News & Updates

Off-label targeted drugs improve survival in CTEPH
Off-label targeted drugs improve survival in CTEPH
26 Jun 2024

Off-label pulmonary arterial hypertension (PAH)-targeted drugs may increase long-term survival in patients with chronic thromboembolic pulmonary hypertension (CTEPH), as shown in a study.

Off-label targeted drugs improve survival in CTEPH
26 Jun 2024
Working out in the COVID aftermath: How intense can one go?
Working out in the COVID aftermath: How intense can one go?
26 Jun 2024 byAudrey Abella

Outpatients with post-COVID condition (PCC) generally tolerated exercise without significant worsening of symptoms or decline in aerobic performance after 48 hours. However, they had lower muscle strength and aerobic capacity than controls, and even showed signs of POTS* and myopathy in a randomized crossover trial.

Working out in the COVID aftermath: How intense can one go?
26 Jun 2024
Diabetes ups mortality risk in TB patients
Diabetes ups mortality risk in TB patients
25 Jun 2024 byStephen Padilla

People diagnosed with tuberculosis (TB) face a worse prognosis if they also have untreated or complicated diabetes mellitus (DM), according to a study.

Diabetes ups mortality risk in TB patients
25 Jun 2024
Subcutaneous amivantamab compares favourably with intravenous dosing in EGFR-mutant NSCLC
Subcutaneous amivantamab compares favourably with intravenous dosing in EGFR-mutant NSCLC
18 Jun 2024 byJairia Dela Cruz

In previously treated patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC), subcutaneous (SC) amivantamab combined with lazertinib shows noninferior pharmacokinetic and efficacy profiles compared with the approved intravenous (IV) formulation of amivantamab, according to the phase III PALOMA-3 trial.

Subcutaneous amivantamab compares favourably with intravenous dosing in EGFR-mutant NSCLC
18 Jun 2024
NMR helps tailor treatment for smoking cessation in smokers with COPD
NMR helps tailor treatment for smoking cessation in smokers with COPD
18 Jun 2024

Among smokers with chronic obstructive pulmonary disease (COPD), use of varenicline seems better than bupropion in normal metabolizers, but bupropion displays similar efficacy and less side effects in slow metabolizers, reports a study.

NMR helps tailor treatment for smoking cessation in smokers with COPD
18 Jun 2024